Review

Solution NMR Studies of *Mycobacterium tuberculosis* Proteins for Antibiotic Target Discovery

Do-Hee Kim †, Sung-Min Kang † and Bong-Jin Lee *

Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 151-742, Korea; ozmagic15@snu.ac.kr (D.-H.K.); men0528@snu.ac.kr (S.-M.K.)

* Correspondence: lbj@nmr.snu.ac.kr; Tel.: +82-2-880-7869

† These authors contributed equally to this work.

Received: 31 July 2017; Accepted: 27 August 2017; Published: 31 August 2017

Abstract: Tuberculosis is an infectious disease caused by *Mycobacterium tuberculosis*, which triggers severe pulmonary diseases. Recently, multidrug/extensively drug-resistant tuberculosis strains have emerged and continue to threaten global health. Because of the development of drug-resistant tuberculosis, there is an urgent need for novel antibiotics to treat these drug-resistant bacteria. In light of the clinical importance of *M. tuberculosis*, 2067 structures of *M. tuberculosis* proteins have been determined. Among them, 52 structures have been solved and studied using solution nuclear magnetic resonance (NMR). The functional details based on structural analysis of *M. tuberculosis* using NMR can provide essential biochemical data for the development of novel antibiotic drugs. In this review, we introduce diverse structural and biochemical studies on *M. tuberculosis* proteins determined using NMR spectroscopy.

Keywords: *Mycobacterium tuberculosis*; antibiotic target; nuclear magnetic resonance (NMR); biomolecular interaction

1. Introduction

*Mycobacterium tuberculosis* quickly became a global epidemic in the 18th century and continues to threaten global health in the 21st century. Genome comparison of *M. tuberculosis* with other bacteria revealed characteristics of both Gram-negative and Gram-positive bacteria. This unique characteristic of *M. tuberculosis* provides insights into the pathogenicity of *M. tuberculosis* based on phylogenetic analysis [1].

Tuberculosis (TB) is a powerful infectious disease that has been present in humans for more than 15,000 years. TB spreads via the respiratory tract from infected people or the gastrointestinal route via contaminated food and triggers severe pulmonary diseases [2]. TB causes approximately 2 million deaths every year. Furthermore, current pharmaceutical therapies show clear limits in the cure rate [3]. TB control is highly vulnerable to multidrug resistance (MDR)-TB epidemics because of inadequate treatment and increasing resistance. More than 350,000 new cases of MDR-TB occur annually [4]. In addition, extensively drug-resistant tuberculosis strains (XDR-TB), which are resistant to fluoroquinolones and second-line injectables, have been reported and the use of ethionamide as second-line treatment is not very effective [5]. Because of increases in drug-resistant tuberculosis (MDR-TB and XDR-TB), there is an imminent need for new drug candidates with alternative mechanisms of action.

To discover novel antibiotic candidates, new pharmaceutical agents for *M. tuberculosis* that can relieve the current danger associated with drug-resistance should be developed. Bacterial genome-sequencing may be useful for antibiotic resistance detection. Genome-sequencing experiments of pathogenic bacteria have revealed much information and provided valuable contributions to disease surveillance [6]. For *M. tuberculosis*, the complete genome sequence of the most well-characterized
strain H37Rv contains 4,411,429 base pairs. H37Rv contains more than 4000 genes and encodes 3924 proteins. These proteins can be assigned to several large subgroups according to their functions: hypothetical proteins, metabolic pathways including proteins for carbohydrate and lipid metabolism, transcription-regulating proteins, drug resistance-hosting proteins, and immune-related proteins [7]. In one gene cluster of *M. tuberculosis*, 122 genes are related to more than three essential metabolic pathways; among them, 55 genes are predicted to be indispensable for survival and the maintenance of *M. tuberculosis* [8]. Based on these bioinformatics data, proteins in *M. tuberculosis* contain various novel therapeutic targets.

Considering the clinical importance of *M. tuberculosis*, the protein data bank (PDB) contains a total of 2067 structures of the proteins alone and in complex with binding partners (chemicals or proteins) from this bacterium. Among these structures, 2011 structures (97.3%) were determined by X-ray crystallography, 52 structures (2.5%) were determined by nuclear magnetic resonance (NMR) spectroscopy, and four structures (0.2%) were determined by electron microscopy.

Despite its size limitations, NMR spectroscopy is a powerful tool for revealing the atomic structure of macromolecules in solution. NMR can provide essential biochemical data for the development of antibiotic drugs with novel mechanisms of action. Therefore, functional details based on structural analysis of *M. tuberculosis* using NMR are significant. In this review, we introduce the diverse structural and biochemical studies of *M. tuberculosis* proteins based on NMR experiments. Valuable findings based on chemical shift perturbation and ligand-binding studies reveal information regarding biophysical mechanisms and dynamics of target proteins, which can be applied for anti-tuberculosis drug discovery.

### 2. NMR Structures

Overall structures of target proteins provide information for understanding the mechanisms of action and binding sites, as well as others. With various NMR techniques, biochemical studies can be conducted. Thus, the solution structures of several target proteins from *M. tuberculosis* have been studied using NMR spectroscopy. We categorized the proteins structures according to their functions in Table 1. Representative structures are shown in Figures 1 and 2, and the details are introduced below.

| Classification | Protein | Brief Description | PDB ID (Deposit Year) |
|----------------|---------|-------------------|-----------------------|
| Transport-related proteins | Rv2244 | Acyl carrier protein | 1KLP (2001) |
| | Rv3250c * | Electron transport | 2KN9 (2009) |
| | Rv1739c | Sulfate transporter | 2KLN (2009) |
| Transcription-related proteins | MT3852 | ArsR family, transcription regulator, nickel metal sensor | 2LKP (2012) |
| | Rv1994c | ArsR family, transcription regulator, cadmium metal sensor | 2JSC (2013) |
| | Rv0639 * | Transcription elongation–termination factor | 2M16 (2013) |
| | Rv2050 * | RNA polymerase-binding protein | 2M4V (2013) |
| Nucleotide-binding proteins | J113_05350 | DNA-binding response regulator | 2RVS (2015) |
| | Rv3597c * | Nucleoid-associated protein | 2KN6 (2009) |
| Ser/Thr Protein kinase-related proteins | Rv0014c | Ser/Thr protein kinase (STPK) PknB | 2KUD, 2KUE, 2KUF, 2KUI (2010) |
| | Rv1827 | Substrate of STPK PknB | 2KFL (2009) |
| | Rv0206c | Substrate of STPK PknB | 2LC1, 2LC2 (2011) |
| | Rv2175c | Substrate of STPK PknL | 2KJS (2009) |
| | Rv2223 * | Protein-tyrosine Phosphatase | 2LJQ (2012) |
| | Rv0732 * | Transferase, adenylate kinase | 1P4S (2003) |
| Enzymes and related proteins | Rv1089 | Hydrolase, Resuscitation-promoting factor | 1XSF (2004) |
| | Rv1884c | Hydrolase, Resuscitation-promoting factor | 2NSZ (2015) |
| | Rv1014c * | Hydrolase, peptidyl-tRNA hydrolase | 2J8C (2007) |
| | Rv2737c | Hydrolase, endonuclease | 2L8L (2011) |
| | MT1859 | Hydrolase | 2LQJ (2012) |
| | Rv3914 | Thioredoxin | 2L59, 2L4Q (2010) |
| | Rv3198.1 | Mycothiol-dependent reductase | 2LQQ, 2LQO (2012) |
Table 1. Overview of NMR structures from *M. tuberculosis* proteins.

| Classification          | Protein                  | Brief Description                             | PDB ID (Deposit Year) |
|-------------------------|--------------------------|-----------------------------------------------|-----------------------|
| Siderophore-related     | Rv2377c *                | Siderophore biosynthesis                      | 2KHR (2009)           |
|                         | Rv0451c                  | Siderophore export                            | 2LWC (2012)           |
|                         | Rv2875                   | Immunogenic protein MPT70                      | 1NYO (2003)           |
|                         | Rv1980c                  | Immunogenic protein MPT64                      | 2HII (2006)           |
|                         | Rv3879/MB3904            | Type VII secretion system protein              | 1WA8 (2004)           |
|                         | Rv0287/Rv0288            | Type VII secretion system protein              | 2KG7 (2009)           |
| Secreted proteins       | Rv0603                   | Immune system                                 | 2KGY (2009)           |
|                         | Rv1761c                  | Membrane protein                              | 2KSM (2008)           |
|                         |                          |                                               | 2KGS, 2KGW (2009)     |
|                         |                          |                                               | 2KSM (2010)           |
|                         |                          |                                               | 2L26 (2010)           |
|                         |                          |                                               | 2LBT, 2LCA (2011)     |
| Membrane proteins       | Rv0899                   | Pore-forming outer membrane protein            |                      |
|                         |                          |                                               |                      |
| Uncharacterized proteins| Rv2302                   | Unknown function                              | 2A7Y (2005)           |
|                         | Rv0543c                  | Domain of Unknown Function DJU3349 (PF11829)  | 2KVC (2010)           |
|                         | Rv3148c                  | Chaperone                                     | 1P92, 1P93 (2003)     |
|                         | Rv1311                   | ATP synthase epsilon chain                    | 2LX5 (2012)           |
|                         | Rv0431                   | Vesiculogenesis and immune response regulation | 2MSY (2013)           |
|                         | Rv3682 *                 | Penicillin binding protein                     | 2MGV (2013)           |
|                         | Rv1466                   | [Fe-S] cluster assembly related protein        | 5IRD (2016)           |
|                         | Rv2171                   | Lipoprotein                                   | 2NC8 (2016)           |
| Other proteins          |                          |                                               |                      |
|                         |                          |                                               |                      |
| * Proteins, analyzed as potential drug targets for *M. tuberculosis* in this paper. |

Figure 1. Ribbon representation of NMR structures of *M. tuberculosis* proteins. Transport-related proteins (A) Rv2244 (PDB ID 1KLP); (B) Rv3250c (PDB ID 2KN9); (C) Rv1739c (PDB ID 2KLN). Transcription-related proteins (D) Rv1994c (PDB ID 2JSC); (E) MT3852 (PDB ID 2LKP); (F) Rv0639 (PDB ID 2M16); (G) Rv2050 (PDB ID 2M4V). Nucleotide-binding proteins (H) J113_05350 (PDB ID 2RV9); (I) Rv3597c (PDB ID 2KNG); Ser./Thr Protein kinase-related proteins (J) Rv0014c (PDB ID 2KUI); (K) Rv1827 (PDB ID 2KFU); (L) Rv0020c (PDB ID 2LC0 (Left) and 2LC1 (Right)); (M) Rv2175c (PDB ID 2KFS); (N) Rv2234 (PDB ID 2LUO). Secondary structural elements, α-helix, β-sheet, and loop are colored in red, yellow, and green, respectively.
The carboxyl-terminus of AcpM known as a “molten domain” showed increased mobility.

The topology of AcpM is “square” [12] comprising four α-helices that form a right-turn helical bundle (Figure 1A). The overall structure of Rv3250c known as a “molten domain” showed increased mobility as demonstrated by decreased $^1$H-$\text{^{15}}$N HetNOE values and solvent exchange/accessibility data.

Rv3250c, also known as rubredoxinB, is a small nonheme iron-binding protein involved in the electron-transfer process [13]. Because of their roles in electron-transfer processes, rubredoxin proteins are considered potential drug targets for M. tuberculosis. The overall structure of Rv3250c consists of one three-stranded antiparallel β-sheet ordered in β3-β1-β2 and a $\alpha_{10}$-helix connected to the N-terminus of β3 (Figure 1B), as well as a zinc that is tetrahedrally coordinated to the S atom of four cysteine residues.
residues (Cys9, Cys12, Cys42 and Cys45). This structure containing Cys4-type metal coordination and a three-stranded antiparallel $\beta$-sheet is common in rubredoxin proteins associated with various metals [14–17].

$sulp$ is related to the transport of the $SO_4^{2-}$, and most bacterial SulP proteins and eukaryotic SulP/SLC26 proteins include a C-terminal cytoplasmic sulfate transporter anti-$\sigma$ factor antagonist (STAS) domain [18]. As the SulP/SLC26 anion transporter, the STAS domain of Rv1739c (residues 437–560) adopts an anti-$\sigma$ factor antagonist fold containing five $\alpha$-helices and a four-stranded parallel $\beta$-sheet (Figure 1C) [19].

2.2. Transcription-Related Proteins

*M. tuberculosis* encodes approximately 10 arsenic repressor (ArsR) family proteins as one of the metallo-regulatory proteins that modulate the transcription of metal ion transporters [20,21]. ArsR proteins play roles in the expression of genes encoding proteins related to metal ion detoxification, sequestration, efflux, and possibly other processes [22]. In *M. tuberculosis*, two structures of ArsR family regulators, Rv1999c, CmtR [23] and MT3852, NmtR from *M. tuberculosis* strain CDC 1551/Oshkosh [24], were determined by NMR. As metal-responsive transcriptional regulators, CmtR and NmtR are DNA-binding repressors that sense cadmium and nickel, respectively. Their overall structures form a symmetric dimer and exhibit the typical core winged-helix fold of the ArsR family. The topology of the monomer includes five $\alpha$-helices and two $\beta$-sheets arranged in a $\alpha_1$-$\alpha_2$-$\alpha_3$-$\alpha_4$-$\alpha_5$-$\beta_1$-$\beta_2$-$\alpha_5$-fold (Figure 1D,E). As the DNA recognition helix, helix $\alpha_4$ is also denoted as $\alpha_R$, and the $\beta$-wing tip is structurally less well-defined than the core of the molecule. NmtR has distinct long flexible N- and C-terminal tails compared to CmtR.

Rv0639, also known as N-utilization substances G (MtNusG), is a small molecule regulator that modulates the movement of RNA polymerase (RNAP) along DNA [25,26]. NusG is essential in Gram-negative bacteria, and an inhibitor of the NusG-RNAP interaction may be a drug target [27]. The solution NMR structure of MtNusG-CTD (residues 178–238) is composed of five $\beta$-strands folded into an antiparallel barrel-type $\beta$-sheet in the order of $\beta_5$-$\beta_1$-$\beta_2$-$\beta_3$-$\beta_4$ (Figure 1F). Additionally, to investigate transient domain interactions, titration of unlabeled MtNusG-CTD into $^{15}$N-labeled MtNusG-NTD was conducted, but there was no significant change in the spectrum. For further analysis, $^{15}$N relaxation measurements were performed. Because the $R_1$ and $R_2$ rates are sensitive to the tumbling of proteins and are related to the rotational correlation time, the $R_2/R_1$ ratio indicates molecular reorientation in solution [26]. The calculated $R_2/R_1$ ratio of NusG showed a different distribution of residues from MtNusG-CTD and MtNusG-NTD, indicating a different reorientation on the timescale of molecular rotation. Thus, there are no tight domain interactions for MtNusG.

Rv2050 is RNAP-binding protein A (RbpA) and affects transcription by binding to the $\beta$ subunit of RNAP. It is also related to the response of *M. tuberculosis* to the anti-TB drug rifampicin [28]. RNAP contains a core of five subunits ($\alpha_2$ and $\beta$) and a sixth $\sigma$-subunit (or $\sigma$ factor) which is involved in promoter recognition and transcription initiation [28,29]. Hu et al. found that stabilizing the formation of the RNAP holoenzyme containing $\sigma^A$ by RbpA activates transcription [30]. These roles of RbpA such as gene expression regulation, normal growth of *M. tuberculosis*, and rifampicin tolerance make RbpA as a drug target. The structure of RbpA (residues 1–79) comprises four $\beta$-strands forming two antiparallel $\beta$-sheets connected by turns and loops (Figure 1G). The two $\beta$-sheets appear as a $\beta$-sandwich-like structure and are stabilized by aromatic and non-polar residues (Tyr32, Val42, Phe44 and Trp54).

2.3. Nucleotide-Binding Proteins

The PhoP-PhoR (PhoPR) two-component system of *M. tuberculosis* is involved in microbial adaptation [31]. PhoP is known to regulate numerous genes related to cellular functions and is involved in *M. tuberculosis* virulence [32]. Therefore, understanding its structure and function is important. The J113_05350, PhoP protein from *M. tuberculosis* CAS/NITR204, has two folded domains, an N-terminal
receiver domain phosphorylated by PhoR (PhoPN; residues 1–138) and C-terminal effector domain that binds DNA (PhoPC; residues 150–247) [33]. The structure of the PhoPC DNA-binding domain was evaluated to determine the mechanism of DNA binding and the structural role of the interdomain linker [34]. The overall structure of PhoPC (residues 142–247) consists of two β-sheets packed against a three-helix bundle in the order of β6-β7-β8-β9-a6-β10-a7-a8-β11-β12 (Figure 1H). The elevated mobility of the loop connecting a7 and a8 (a7/a8 loop, residues 206–211), N-terminus, and K230 and V239 was observed from the 1H-15N-HetNOE and RCI-S2 data.

Rv3597c, also known as Lsr2, consists of an N-terminal dimerization domain and C-terminal DNA-binding domain [35]. As a nucleoid-associate protein, Rv3597c binds to AT-rich sequences and various genes related to virulence, antigenicity, and cellular processes such as DNA replication, transcription, and protein synthesis [36]. When lsr2 is up-regulated under hostile conditions within the host, inhibition of the expression of the above genes allows M. tuberculosis to remain latent [36]. Lsr2 is thought to be a unique drug target for controlling latent tuberculosis infection. NMR was used to solve the structure of the C-terminal DNA-binding domain of Lsr2 (Lsr2C, residues 66–112), which is composed of two α-helices (α1, residues 78–89; α2, residues 102–112) connected by a long loop and packed through hydrophobic interactions (Figure 1I).

2.4. Ser/Thr Protein Kinase-Related Proteins

M. tuberculosis expresses a eukaryotic like kinase-signaling network consisting of 11 predicted Ser/Thr protein kinases (STPKs) (named as PknA–PknL, except for PknC) [37], at least one Ser/Thr phosphatase (PstP) and two PTPs (PtpA and PtpB) [38], and five pThr-binding Forkhead-associated (FHA) domain-containing proteins [39]. These proteins are involved in diverse stages of growth, development, and pathogenesis in M. tuberculosis [40]. Thus, STPKs and related proteins are attractive targets for inhibitor development. There have been several NMR studies of STPK, phosphatase, and FHA domain functions to reveal structural information for the proteins and the signaling pathways of M. tuberculosis.

Because of its importance in mycobacterial growth, PknB is considered a drug target [41]. Rv0014c, PknB is a transmembrane STPK and possesses extracellular penicillin and Ser or Thr kinase-associated (PASTA) domain, which is a signaling molecule [42]. To investigate the regulation of PASTA domain-mediated PknB activity, structural studies were conducted using NMR [43]. Because of the large size of the PASTA domain, structure determination was conducted using the proteins dissected into three overlapping bidomain constructs: PknB_PASTA12 (residues 354–491; PDB ID 2KUD), PknB_PASTA23 (residues 423–557; PDB ID 2KUE), and PknB_PASTA34 (491–626; PDB ID 2KUF), corresponding to domains 1–2, 2–3 and 3–4, respectively. The overall secondary structure topology was β′-α1-β1-β2-β′’-β3. Based on these structures and small-angle light scattering experiments, the overall structure of the PASTA domain was modeled (PDB ID 2KUI) (Figure 1I).

As substrates of PknB, Rv1827 and Rv0020c, which have FHA domains, were studied. Rv1827 is specifically phosphorylated at Thr22 within a conserved N-terminal T21T22SVF motif that is the preferred PknB target sequence [44]. To investigate the regulation mode of the FHA domain at the molecular level, solution structures of Rv1827 and Rv1827-pThr22 were determined using multidimensional heteronuclear NMR [45]. Rv1827 contains a classical FHA domain fold comprising an 11-stranded β-sandwich topology (Figure 1K). The conserved residues, Arg81 and Ser95, contact pThr22. The linker region (residues 34–54) and extreme N- and C-termini of Rv1827 were not well-defined. 15N relaxation data represented by [1H]–15N HetNOE, T1, and T2 values also showed increased internal mobility of these regions. The dynamic behavior of the region containing pThr22 exhibited similar characteristics to the core FHA domain. Rv0020c contains 527 amino acid sequences. For structural and interaction studies, the N-terminal domain (PDB ID 2LC0, residues 1–132) and FHA domain (PDB ID 2LC1, residues 430–527) structures were determined [46]. The N-terminal domain contains a three-stranded β-sheet faced on one side by two amphipathic α-helices (α1, α3) with a topology of α1-β3-α3-β1-β2. This αβ sandwich is capped by the short helix α2 (Figure 1L). The FHA
domain of Rv0020c also adopted the global FHA domain fold composed of an 11-stranded \( \beta \)-sandwich topology (Figure 1L).

The structure of Rv2175c as a substrate of PknL was also determined [47]. Rv2175c has two domains: an N-terminal winged helix-turn-helix motif (residues 18–77), a DNA-binding domain, and C-terminal effector domain (residues 78–146), and contains six \( \alpha \)-helices and two \( \beta \)-strands (Figure 1M). There is some flexibility between the two domains. The solution structure of Rv2175c revealed that the N-terminal part (Met1–Ile16) and large loop (Thr110–Asn122) were disordered. The chemical shift perturbations of Rv2175c according to the phosphorylation of Thr9 showed no significant structural change in the monomer, but electrophoretic mobility shift assay experiments showed that the phosphorylation of Thr9 negatively affected its DNA binding.

Rv2234 is a low-molecular weight protein-tyrosine phosphatase (LMW-PTP) and is also known as MptpA. Because Rv2234 is essential for the survival of \( M. \) \( \text{tuberculosis} \) upon infection of host macrophages, it is considered a drug target [48]. The structure of Rv2234 exhibits a Rossman fold which is common in LMW-PTPs containing a four-stranded parallel \( \beta \)-sheet connected via five \( \alpha \)-helices in the order of \( \beta_1-\alpha_1-\beta_2-\alpha_2-\alpha_3-\beta_3-\alpha_4-\beta_4-\alpha_5 \) (Figure 1N) [49]. The highly conserved active site of LMW-PTPs involves the residues Cys11-Thr-Gly-Asn-Ile-Cys-Arg-Ser18 positioned in a loop known as the phosphate-binding loop (P-loop), and the catalytic active residues is Cys11. The \( \beta_2-\alpha_2 \) loop containing residue Trp48 (W-loop, Gly44–Asp55) and \( \beta_4-\alpha_5 \) loop containing critical residue Asp126 (D-loop, Arg111–Asp131) are positioned close to the P-loop. Additionally, Trp48 and His49 are involved in substrate specificity and Asp126 is crucial for the catalytic mechanism.

2.5. Enzymes and Related Proteins

Rv0733 is known as an adenylate kinase (AK), which is involved in energy metabolism and nucleic acid synthesis [50]. As an essential enzyme in metabolism and because of its unique catalytic properties [51], AK is considered a novel target for anti-TB drugs. The protein is composed of nine \( \alpha \)-helices and five \( \beta \)-strands and contains an ATP-binding motif that binds the phosphates of ATP (Figure 2A) [52]. This motif is termed as the P-loop and is represented as GXXGXGK which ranges from residues 7 to 13 in Rv0733.

Resuscitation-promoting factor (RPF) proteins is related to normal proliferation of dormant bacteria and is involved in reactivation of stationary-phase cultures of (G + C)-rich Gram-positive bacteria, including \( M. \) \( \text{tuberculosis} \) [53,54]. Therefore, understanding the functional activity of RPF proteins will provide an insight for the development of anti-TB drugs. \( M. \) \( \text{tuberculosis} \) encodes five RPF proteins (A–E) [55] and two RPF proteins among them, Rv1009 (also known as RpfB) [56] and Rv1884c (also known as RpfC) [57], have been studied using NMR. The solution structure of the C-terminal 108 residue core domain of RpfB (RpfBc) is composed of five \( \alpha \)-helices (Figure 2B). RpfBc shares high structural homology with c-type lysozymes (PDB ID 3LZT, Z-score of 6.4, r.m.s. deviation of 2.9 Å over 79 residues) [58]. The solution structure of the RpfC catalytic domain consists of four \( \alpha \)-helices with an N-terminal flexible tail (Figure 2C). The catalytic residue Glu16 is positioned on the \( \alpha_1 \) helix. The unstructured C-terminus is anchored to the N-terminus of the domain through a disulfide bond (Cys15–Cys76).

Rv1014c, also known as MtPth, is peptidyl-tRNA hydrolase (Pth) [59]. The unique properties and importance of Pth in bacteria and synergistic effect of Pth inhibitors with macrolide antibiotics suggest Pth is an attractive antibiotic target [60]. Rv1014c consists of central seven \( \beta \)-sheet encompassed by six \( \alpha \)-helices and additional two \( 3_{10} \) helices (\( 3_{10}-1 \) and \( 3_{10}-2 \)) (Figure 2D). The catalytic base His22 of MtPth is positioned in a short segment between the \( 3_{10}-1 \) helix and \( \alpha_1 \) and is exposed on the surface of the structure. The backbone dynamics measured by \( ^{15} \)N relaxation experiments revealed overall rigidity of this enzyme with \( \tau_m \) of 9.67 ± 0.02 ns. The segments between the \( 3_{10}-1 \) helix and \( \alpha_1 \) and C-terminal helical hairpin of the protein undergo ms to µs timescale motions and may be related to the interaction with the substrate peptidyl-tRNA.
MT1859 from *M. tuberculosis* strain CDC 1551/Oshkosh, also known as MgtC, is a virulence factor related to survival inside macrophages in *M. tuberculosis* as other intracellular bacterial pathogens [61]. The structure of the C-terminal domain adopts the fold of an aspartokinase, chorismate mutase, and TyrA (ACT) domain which is a small molecule-binding domain comprised of a $\beta_3\alpha_3\beta_3\alpha_3\beta$ fold (Figure 2E) [62].

The thioredoxin system is essential for redox homeostasis and maintains cellular proteins in a reduced state [63]. The thioredoxin system in *M. tuberculosis* is composed of three thioredoxins (TrxA, TrxB, and TrxC) and one thioredoxin reductase (TrxR), in which Trx becomes oxidized, and is reduced by TrxR [64]. Because of the low similarity (35%) of *M. tuberculosis* thioredoxin with human thioredoxin and its importance in oxidative stress, inhibitors selectively targeting the thioredoxin system in *M. tuberculosis* may be developed as anti-mycobacterial drugs [65]. In this context, Rv3914, TrxC was studied using NMR [65]. The structures of TrxC were determined in two states: oxidized (PDB ID 2L59) and reduced (PDB ID 2L4Q). TrxC in both states contains a common fold of four $\alpha$-helices surrounding a five stranded $\beta$-sheet core composed of three parallel strands and two antiparallel strands (Figure 2F).

Rv3198.1, known as mycoredoxin-1 (Mrx1), is mycothiol-dependent reductase. As a novel member of the Trx-family, Mrx1 uses the MSH electron transfer pathway to reduce disulfides in *M. tuberculosis* and is related to several external stresses including oxidative stress, alkylating agents, and antibiotics [66,67]. The structure of Mrx1 was determined in two states, oxidized (PDB ID 2LQQ) and reduced (PDB ID 2LQO) [67], and contains a thioredoxin-fold composed of a four-stranded antiparallel $\beta$-sheet encompassed by three $\alpha$-helices (Figure 2G), which is found in several oxido-reductases [68]. TrxC and Mrx1 have a redox active CXXC motif [68] at the N-terminus of $\alpha_2$ (Cys37-Gly-Pro-Cys40) and $\alpha_1$ (Cys14-Gly-Tyr-Cys17), respectively, and a conserved proline opposite to the active site is present in the cis conformation.

### 2.6. Siderophore-Related Proteins

Because iron is an essential nutrient in most bacterial pathogens, disruption of the biochemical pathway for the sequestration of iron may be a target for novel antibiotics [69,70]. *M. tuberculosis* uses two siderophores, mycobactins and carboxymycobactins, to scavenge iron from the human host [71,72]. Two siderophore-related proteins have been studied by NMR in *M. tuberculosis*.

Rv2377c, MbtH, is a small, 71-residue protein, and one of the proteins composing non-ribosomal protein synthetase clusters involved in siderophore and antibiotic peptide synthesis [73]. The structure of Rv2377c is composed of a three-stranded anti-parallel $\beta$-sheet ordered in $\beta_3$-$\beta_1$-$\beta_2$ and one C-terminal $\alpha$-helix (Figure 2H) [74]. Dynamic experiments revealed the $\mu$s to ms time scale motion of the interface between $\beta_1$–$\beta_2$ and disordered C-terminus region. This dynamic property of the regions containing conserved residues of MbtH-like family may be associated with diverse biological functions and various specific substrates [74].

Rv0451c, known as MmpS4, interacts with MmpL4 which transports small molecules. MmpS4/MmpL4 acts as a siderophore export system in *M. tuberculosis* [75]. The structure of the C-terminal soluble domain Rv0451c (residues 52–140) contains seven consecutive $\beta$-strands arranged in two layers, with $\beta_4$-$\beta_1$-$\beta_6$-$\beta_7$ in one layer and $\beta_3$-$\beta_2$-$\beta_5$ in the other layer (Figure 2I). Interestingly, Rv0451c shows no similarity to proteins with known function such as periplasmic adapter proteins from drug efflux systems of Gram-negative bacteria [76], except for an uncharacterized protein from *Parabacteroides distasonis* (PDB ID 2LGE). This indicates that MmpS4 represents a novel class of accessory proteins in complex transporter systems.

### 2.7. Secreted Proteins

Because secreted proteins from *M. tuberculosis* are targeted by the host immune system, the proteins have been investigated for vaccine development and immunodiagnostics [77]. Several secreted proteins from *M. tuberculosis* have been studied by NMR spectroscopy.
There are two reported solution structures of immunogenic proteins secreted from *M. tuberculosis*. Rv2875, known as immunogenic protein MPT70, folds into a seven-stranded β-barrel flanked by eight α-helices (Figure 2) [78]. Rv2785 shares structural homology with FAS1 domains 3 (Fas3) and 4 (Fas4) of fasciclin I (PDB ID 1O70) [79]. Based on the sequence and structural homology with FAS1 domains from extracellular protein (fasciclin I and βig-h3) that are involved in the interactions between cell surface and extracellular matrix proteins supports the role of Rv2875 in binding to host cell surface proteins [78].

Rv1980c, known as MPT64, has a pseudo-two-domain and adopts a novel fold containing a β-grasp-like motif in the N-terminal region which includes long α-helix (residues 42–60) contacts at a shallow angle against a plane formed from a seven-strand β-sheet (Figure 2K) [80]. Rv1980c antigen is currently utilized to detect active TB infection [81,82].

*M. tuberculosis* utilizes five type VII secretion systems to export several proteins such as Esx family members [83]. Esx proteins are related to TB pathogenesis and survival in host cells, and are associated with metal ion acquisition [84–87]. Several Esx pairs such as including EsxA/EsbB, EsxG/EsxH (Rv0287/Rv0288), EsxR/EsxS (Rv3019c/Rv3020c), and EsxO/EsxP (Rv2346c/Rv2347c) form tight complexes in their functional forms [88–90]. Among them, the structure of EsxA/EsbB (Rv3875/Mb3904 from *M. bovis*) (Figure 2L) [91] and EsxG/EsxH (Rv0287/Rv0288) (Figure 2M) [92] were studied by NMR. The overall structure of both complexes forms a 1:1 heterodimer and is made up of two similar helix-turn-helix hairpin structures originating from individual proteins. To form a four-helix bundle, proteins utilize an extensive hydrophobic contact surface lying antiparallel to each other. Commonly, the long flexible arms at N- and C-termini of both proteins are disordered. However, structural distinctions between two complexes exist. EsxG and EsxH have shorter helices at the N-terminus than EsxA and EsxB, and EsxB shows a helical conformation at the C-terminus. Additionally, EsxG/EsxH has a specific Zn$^{2+}$ binding site detected by NMR titration experiments on a noticeable cleft as a functional site, unlike EsxA/EsbB. These features contribute to the distinct functional roles of two Esx family complexes; EsxA/EsbB is involved in pathogen-host cell signaling and EsxG/EsxH has been implicated in metal ion scavenging [87,90,92].

### 2.8. Membrane Proteins

Rv0899, also known as OmpATb, has been reported to be a pore-forming protein, and under low pH conditions is involved in the permeability of several small, water-soluble molecules [93,94] and self-defense mechanism through ammonia secretion [95]. Additionally, expression of OmpA only in pathogenic species support its role in the virulence of these mycobacterial strains [94]. To investigate the roles of Rv0899, several structural studies using NMR have been conducted [96–99] with various constructs. Rv0899 is divided into three domains: N-terminal domain (residues 1–72) including a membrane-anchoring sequence, central domain (residues 73–200), and C-terminal domain (residues 201–326). The structure of the central domain shares homology with the BON (bacterial OsmY and nodulation) superfamily (pfam04972) [100], containing a six-stranded parallel/antiparallel β-sheet facing three parallel/antiparallel α-helices (Figure 2N). The C-terminal domain consists of four α-helices and four β-strands with αβαβαβαβ topology (Figure 2N) that is the typical α/β-structure of peptidoglycan-binding domains in the OmpA-like superfamily (pfam00691) [101].

### 2.9. Uncharacterized Proteins

Rv2302 is comprised of 80 amino acids and has an unknown function, but is highly conserved in *M. tuberculosis* [102]. The solution structure of Rv2302 folds into a five-strand antiparallel β-sheet with a β-sheet twist flanked by a C-terminal α-helix (Figure 2O). The absence of 2D $^1$H–$^{15}$N HSQC crosspeaks for residues between the β1 and β2 (loop L1) revealed an ms to µs timescale motion of the loop L1 region. $^1$H–$^{15}$N-HetNOE results revealed that the overall structure was rigid except for the N- and C-termini. In the surface representation, a positively charged pocket composed of Arg18, Arg70,
and Arg74 can be observed. As Arg18 is positioned in loop L1 which shows intermediation motion, Arg18 is considered to play a role in the biochemical function of Rv2302.

Rv0543c is the protein categorized in the Domain of Unknown Function (DUF) and belongs to the DUF3349 (PF11829) superfamily [103]. The structure which was determined by NMR is composed of a bundle of five α-helices containing highly conserved hydrophobic residues inside (Figure 2P). The backbone dynamics revealed by 15N relaxation experiments showed the restricted flexibility of overall residues except the unstructured C-terminus.

2.10. Other Proteins

Rv0431 is involved in regulating membrane vesicles of M. tuberculosis and is known as the vesiculogenesis and immune response regulator (VirR) [104]. Following the deletion of highly hydrophobic residues, the truncated protein (residues 42–164) structure was intrinsically disordered in the first 35 amino acids in the N-terminus, and the residual ordered region (residues 78–164) adopted a unique fold containing a five-stranded β-sheet packed by two α-helices on one side and one α-helix on the other (Figure 2Q). Although the mechanism of how VirR regulates vesiculogenesis remains unclear, an intrinsically unstructured region of VirR may be related to the interaction with other proteins.

Rv3682, annotated as PonA2, is one of the two class A penicillin binding proteins (PBPs) of M. tuberculosis. PBPs are enzymes involved in the synthesis, maturation, and recycling of peptidoglycan, which is an essential building block of the bacterial cell wall [105]. Additionally, a C-terminal PASTA domain of PonA2 is related to the adaptation of M. tuberculosis to dormancy [106]. For these properties, Rv3682 is considered an attractive target for inhibitors. The solution structure of the C-terminal PASTA domain of PonA2 (PonA2-PASTA, residues 700–764) exhibits typical PASTA domain topology comprising the N-terminal α-helix followed by a three stranded β-sheet arranged in order of β1-β3-β2 (Figure 2R). Interestingly, PonA-PASTA shows a higher structural similarity with PASTA domains of STPKs than with the PBP2x family [106].

Rv2171, LppM (residues 26–185) has 11 β-strands, a pseudo β-barrel closed by an α-helix, and a degenerated β-strand (Figure 2S) [107]. Although LppM is known as a lipoprotein, it does not share homology with other known lipoproteins from M. tuberculosis, defining a new protein fold. This protein is related to the phagocytosis and efficient blocking of phagosomal acidification in macrophages, resulting in M. tuberculosis persistence [108], and can bind M. tuberculosis phosphatidylmyoinositol mannoside, which is known to affect the host immune response [107].

3. NMR-Based Molecular Interaction

Understanding the molecular mechanism of action from binding information may provide insight for the development of novel antibiotics. Several experimental NMR approaches have been developed to observe interactions between proteins and ligands in solution [109]. Using NMR-based methods, changes in the spectra of the protein or the ligand can be monitored to observe molecular interactions.

3.1. Protein-Observed NMR for Interaction Mode

NMR spectroscopy can be applied for monitoring interactions between target proteins and various molecules. Among several methods, chemical shift perturbation (CSP) analysis is the most widely used technique because of the high sensitivity of 2D 1H–15N HSQC experiments [110]. Additionally, this method typically requires relatively low concentrations and short recording times. Every residue except for proline contains an amide atom, and 2D 1H–15N HSQC data reflect the chemical environment of all parts of the protein. Addition of unlabeled molecules (proteins, metal, nucleic acid) to 15N-labeled proteins alter the chemical environment, resulting in a chemical shift change in the spectrum. Mapping the altered residues on a known structure can provide information such as the binding interface. In studies of proteins from M. tuberculosis, interaction modes with various molecules were detected based on protein-observed NMR methods. Below, we describe some examples.
3.1.1. Rv2050, RbpA

To understand the relationship between full-length RbpA and σ subunits, 2D $^1$H-$^15$N TROSY and 3D $^1$H-$^13$C-$^15$N TROSY-HNCO spectra of isotope-labeled RbpA and isotope-labeled RbpA bound to un labeled His$_6$-$\sigma^B_{1–228}$ were recorded [28]. The backbone amide groups showing evident signal changes by His$_6$-$\sigma^B_{1–228}$ binding included Ala13, Ser15, Tyr16, and 10 unassigned residues. The unassigned RbpA backbone amide groups belonged to the C-terminal region (residues 77–111). This binding experiment indicated that the central domain of RbpA is not directly affected by formation of the complex with His$_6$-$\sigma^B_{1–228}$, but the N- and C-termini are related to binding. RbpA forms a tight complex with His$_6$-$\sigma^B_{1–228}$ via its N- and C-terminal regions.

3.1.2. Rv1739c

The interaction of the STAS domain of Rv1739c with GTP or GDP was investigated in 2D $^1$H-$^15$N HSQC experiments [19]. GDP binding showed chemical shift changes of 16 residues, including Ala10, Arg12, Val13, Gly15, Val41, Asp44, Gln47, Val48, Arg79, Gly106, Glu107, Asp108, His109, Ile110, Arg122, and Arg124 (Figure 3A). GTP also affected the chemical shifts of residues Ala10, Arg12, Val13, Gly15, Val48, Val61, Arg79, His109, and Arg124. CSP analysis of titration experiments revealed significant CSP values were Gly73, Ala74, Ser80–Glu85, Ser95, Ile100, Ala102, and Asp103, and 3D pairs was used in titration experiments utilizing 2D $^1$H–$^15$N HSQC spectra [36]. Residues showing significant chemical shift changes are labeled and colored in green. The disulfide bond is represented in blue color.

Figure 3. The mapping of the binding and conformational change sites on the ribbon representation of M. tuberculosis proteins. (A) GDP binding site of Rv1739c (PDB ID 2KLN); (B) DNA binding site of Rv3597c (PDB ID 2KNG); (C) tri-NAG binding site of Rv1009 (PDB ID 1XSF); (D) Phosphate binding site (Left) and PktA binding site (Right) of Rv2234 (PDB ID 2LUO); (E) Conformational change site by pH of Rv1884c (PDB ID 2NSZ); (F) TrxR binding site of Rv3914 (PDB ID 2L59). The residues showing significant chemical shift changes are labeled and colored in green. The disulfide bond is represented in blue color.
3.1.3. Rv3597c, Lsr2

To monitor the DNA-binding site of Lsr2C, a 27-mer DNA containing nine consecutive A-T base pairs was used in titration experiments utilizing 2D $^1$H–$^{15}$N HSQC spectra [36]. Residues showing significant CSP values were Gly73, Ala74, Ser80–Glu85, Ser95, Ile100, Ala102, and Asp103, and surface mapping showed that the residues were located predominantly on the $\alpha_1$ helix and nearby linker loop (Figure 3B). Based on the results, the Lsr2C-DNA complex structure was predicted using HADDOCK 2.0 [111], and DNA binding of Lsr2c occurred by grabbing either edge of the minor groove of DNA like a clamp.

3.1.4. Rv1009, RpfB

To analyze the binding of RpfBc with oligosaccharide, NAG and its trimer, N,N',N''-triacetyl-chitotriose (tri-NAG) were evaluated in NMR titration experiments [56]. The binding NAG monomer exhibited no chemical shift changes, but the addition of tri-NAG resulted in chemical shift changes at residues in the putative binding groove, including the loop connecting $\alpha_4$ and $\alpha_5$ (Figure 3C). Gln347 was the most affected residue and an equivalent conserved glutamine in the lysozyme (Gln104) was a key residue for binding oligosaccharide.

3.1.5. Rv2234, MptpA

The binding of MptpA with phosphate ion (Pi) as a competitive inhibitor was investigated by comparing 2D $^1$H–$^{15}$N TROSY data with and without NaH$_2$PO$_3$ [49]. Based on the results, six residues (Asn14, Cys16, Trp48, Asp90, Tyr128, and Tyr129) located in the P-loop disappeared because of line broadening. CSP analysis revealed five regions affected by phosphate binding to the active site: Asn14–Met24 (P-loop), Ala43–Glu56 (W-loop), Arg72–Gln75, Lys89 and Asp90, and Asp123–His150 (D-loop and hinge region in $\alpha_5$-helix) (Figure 3D). Phosphate titration experiments showed that the functionally important P-, W-, and D-loop as well as other spatially related regions are involved in the specific binding of phosphate to MptpA.

As MptpA is phosphorylated by the kinase PtkA [112], to understand the binding interface of the MptpA·PtkA complex, a titration experiment was conducted. CSPs were observed during NMR titration analysis of $^{15}$N-labeled MptpA with unlabeled PtkA. The backbone amides of MptpA showing the largest CSP values upon binding of PtkA were Asn14, Cys16, Met20, Ala21, Asn47, Trp48, His49, Gly77, Thr78, Leu89, Asp90, Val124, Glu125, Asp126, Tyr129, Gly148, and His150. Amide resonances of Cys16 and Trp48 were not detected. Mapping of CSPs onto the structure indicated that MptpA·PtkA complex interface contains P-, W-, and D-loop motifs with additional regions, including the residues Met20, Gly77, and Asp90 as well as Ala145 (Figure 3D).

3.1.6. Rv1884c, RpfC

RpfC function via a redox-sensing switch mediated by cysteine residues was assessed using NMR [57]. 2D $^1$H–$^{15}$N HSQC spectra of Rpfc were acquired at pH 7, 5 and 3 in the presence of TCEP to maintain reducing conditions. This experimental condition mimicked the hydrolysis of the disulfide bridge between Cys15 and Cys76. Significant chemical shift changes were observed for residues surrounding the disulfide bond and the residues Leu33, Glu55 and Leu7, which are far from the cysteine residues (Figure 3E). These data indicate that the oxidation state of the cysteine residues modulates the shape of the hydrophobic catalytic cleft via conformational changes.

3.1.7. Rv3914, TrxC

To understand the interaction between TrxC and TrxR, 2D $^1$H–$^{15}$N HSQC spectra of $^{15}$N-labeled TrxC was monitored following the addition of TrxR which was reduced by NADP(H) or DTT [65]. The crosspeaks corresponding to the TrxR binding interface residues of TrxC either disappeared or showed large chemical shift changes. The residues were Phe32, Ala34, Thr35, Trp36, Cys37, Thr67, and
Val78, and these residues form a hydrophobic surface (Figure 3F). Based on the TrxC-TrxR binding interface information obtained from NMR experiments, inhibitor screening was conducted by docking simulation. Among the 10,000 drug-like chemicals, a high scoring compound was selected. Binding was confirmed using 2D $^1$H–$^{15}$N HSQC. Compound CSDDD_6702 showed chemical shift perturbations of several residues including the interface residue Trp31 (HE1). These results provide insight for the design of inhibitors for treating TB.

3.1.8. Rv3682, PonA2

As a penicillin binding protein, PonA2-PASTA was titrated with β-lactam antibiotics (cefuroxime and cefotaxime) \[106\]. The cross peaks of 2D $^1$H–$^{15}$N HSQC exhibited no significant chemical shift perturbations, so it was concluded that PonA2-PASTA is not involved in β-lactam antibiotic binding. To validate whether PonA2-PASTA is involved in a muropeptide-sensing mechanism, two muropeptides typically used to mimic the peptidoglycan peptide stem, L-Ala-γ-D-Glu-mDAP and MurNAc-L-Ala-γ-D-Glu-mdDAP were used in titration experiments. No significant interactions between PonA2-PASTA and muropeptides were observed.

3.2. Ligand-Observed NMR for Drug Discovery

Ligand-based NMR techniques can be applied to detect protein-ligand interactions. This method is efficient because: (i) target protein labeling such as by $^{13}$C or $^{15}$N is not necessary and (ii) small amounts of proteins are needed compared to protein-based NMR. Several methods can be used to monitor changes in the small molecule spectra: saturation transfer difference spectroscopy (STD) \[113\] and Water-LOGSY \[114\], which are NOE effect-based experiments, and DOSY \[115\], which is a diffusion based experiment.

Among them, STD is a popular ligand-based NMR technique for observing molecular interactions. Selective saturation of a resonance belonging to the protein is applied to the sample. If the ligand binds, saturation propagates from the selected protein protons to other protons of the protein via spin diffusion and then saturation is transferred to binding compounds by cross-relaxation at the ligand-protein interface \[113\]. The STD method has been used to characterize the protein-ligand complex. This method can be applied for screening of the efficient ligands as therapeutic targets.

Using several biophysical techniques such as thermal shift screening, isothermal titration calorimetry, and X-ray crystallography, target enzymes from \textit{M. tuberculosis} have been studied to identify inhibitors using ligand-based NMR methods.

3.2.1. Rv3809c, UDP-Galactopyranose Mutase (UGM)

UDP-galactopyranose mutase (UGM) catalyzes the interconversion of UDP-Galp and UDP-Galf \[116\]. Galactofuranose (Galf) is an essential component of galactan chains in the cell walls of mycobacteria \[117,118\]. Therefore, inhibiting Rv3809c, UGM from \textit{M. tuberculosis} (MtUGM) resulting in reduced UDP-Galf is a good strategy for identifying effective anti-TB drugs. Shi et al. revealed a second, druggable binding site of MtUGM using the non-substrate-like UGM inhibitor, MS-208 \[119\]. The elevated STD signal of the inhibitor indicated binding between MtUGM and MS-208. To investigate the binding site of MS-208, competition STD NMR experiments between MS-208 and UDP-Galp, which binds to the S-site, were conducted. By increasing the concentration of each molecule, STD enhancement decreased, indicating competition between MS-208 and UDP-Galp. However, MS-208 binding could not completely eliminate UDP-Galp and the inverse binding. Thus, MS-208 binds at a second site to directly affect substrate binding. UDP, the active site binding ligand of MtUGM, was used in competitive STD NMR experiments. UDP reduced MS-208 binding by approximately 50%, but MS-208 did not significantly affect UDP binding. Therefore, Shi et al. predicted that UDP-Galp/UDP and MS-208 affect the binding of each other through mutual allosteric effects to different degrees. Additional kinetic assays, computational modeling, and mutant experiments
revealed that MS-208 binds to the allosteric binding site (A-site) of MtUGM. The presence of the A-site provides second possible target information for the development of anti-TB pharmaceuticals.

3.2.2. Rv2276, CYP121

The presence of the 20 cytochrome P450 enzymes (CYPs) encoded by the mycobacterium genome suggest the importance of these enzymes. Their relationship with the virulence and survival of mycobacterium also makes CYPs potential targets for the treatment of *M. tuberculosis* infections [120–122]. Rv2276, CYP121 from *M. tuberculosis* is specific to this bacterium and catalyzes the formation of a C–C bond between the two tyrosine residues of the substrate cyclodityrosine (cYY), resulting in the formation of mycocyclosin [123]. Thus, CYP121 is considered the most promising anti-TB drug target among other CYPs. Currently known CYP121 inhibitors with high affinities areazole antifungals that function via a type II azole heme coordination [124,125] Hudson et al. investigated inhibitors targeting CYP121 [126]. Through fluorescence-based thermal shift screening, 66 hits were identified against CYP121 among 665 fragments. 66 chemically diverse hits from a thermal shift assay were further screened by 1D 1H-NMR spectroscopy of STD experiments. The STD spectrum of a fragment hit was recorded in the presence and absence of CYP121 or CYP121 plus cYY. Positive signals in the presence of CYP121 indicated the binding of the fragment to the protein, and additional signals for the aromatic region in the presence of CYP121 plus cYY originating from cYY indicated that the fragment-protein interaction is displaced by cYY and that the fragment binds to the active site of CYP121.

4. Conclusions

In this review, we analyzed the 50 known solution NMR structures of proteins from *M. tuberculosis* as targets for antibiotics. Structural and functional studies and ligand interactions of these target proteins provide important information for drug discovery. From studies of proteins presented in *M. tuberculosis*, information regarding the active site, ligand binding site, and mechanism of action, as well as structures of target proteins, can be obtained.

NMR spectroscopy is a powerful tool for screening inhibitors and searching ligands. Compared to X-ray crystallography, size limitations remain problematic, but this method can provide not only structural information, but also biophysical information including protein-ligand binding and dynamics, which cannot be identified using other methods.

Although NMR structure determination is confined to relatively small and medium size molecules, NMR is valuable when studying structurally flexible protein, difficult to be crystallized. NMR spectroscopy can detect the binding interface and properties of target proteins with their diverse binding partner, such as nucleotides, small molecules or metals. Binding affinities can be explained via chemical shift changes between apo- and bound-form. Furthermore, high resolution NMR spectroscopy can provide confident conformations even for uncrystallizable complexes because of low binding affinity.

Identification of unknown ligand-binding sites would contribute to the development of novel active compounds. Conformational dynamics of the binding sites of target proteins determined by NMR will enable identification of lead compounds and the design of potent inhibitors. Particularly, ligand-based NMR techniques, such as STD, Water-LOGSY, and CPMG NMR pulse programs, have attracted attention as methods for identifying efficient lead compounds. Taken together, these NMR studies of target proteins from *M. tuberculosis* will provide a structural basis for developing novel antibiotics.

Acknowledgments: This work was financially supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (grant number 2014K1A3A1A19067618 and 2015R1A2A1A05001894), and the 2016 BK21plus Project for Medicine, Dentistry and Pharmacy.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Fu, L.M.; Fu-Liu, C.S. Is Mycobacterium tuberculosis a closer relative to Gram-positive or Gram-negative bacterial pathogens? *Tuberculosis* 2002, 82, 85–90. [CrossRef] [PubMed]

2. Hershkovitz, I.; Donoghue, H.D.; Minnikin, D.E.; May, H.; Lee, O.Y.; Feldman, M.; Galili, E.; Spigelman, M.; Rothschild, B.M.; Bar-Gal, G.K. Tuberculosis origin: The Neolithic scenario. *Tuberculosis* 2015, 95 (Suppl. 1), S122–S126. [CrossRef] [PubMed]

3. Keri, R.S.; Chand, K.; Ramakrishnappa, T.; Nagaraja, B.M. Recent progress on pyrazole scaffold-based antimycobacterial agents. *Arch. Pharm.* 2015, 348, 299–314. [CrossRef] [PubMed]

4. Comolet, T. Multidrug-resistant tuberculosis: Challenges of a global emergence. *Bull. Soc. Pathol. Exot.* 2015, 108, 290–298. [CrossRef] [PubMed]

5. Pechalrieu, D.; Lopez, M. Compounds for use in the treatment of mycobacterial infections: A patent evaluation (WO2014049107A1). *Exp. Opin. Ther. Pat.* 2015, 25, 729–735. [CrossRef] [PubMed]

6. Bradley, P.; Gordon, N.C.; Walker, T.M.; Dunn, L.; Heys, S.; Wang, H.; Earle, S.; Pankhurst, L.J.; Anson, L.; de Cesare, M.; et al. Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and *Mycobacterium tuberculosis*. *Nat. Commun.* 2015, 6, 10063. [CrossRef] [PubMed]

7. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Harris, D.; Gordon, S.V.; Eiglmeier, K.; Gas, S.; Barry, C.E., 3rd; et al. Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* 1998, 393, 537–544. [CrossRef] [PubMed]

8. Xu, G.; Ni, Z.; Shi, Y.; Sun, X.; Wang, H.; Wei, C.; Wang, G.; Li, F. Screening essential genes of *Mycobacterium tuberculosis* with the pathway enrichment method. *Mol. Biol. Rep.* 2014, 41, 7639–7644. [CrossRef] [PubMed]

9. Wong, H.C.; Liu, G.; Zhang, Y.M.; Rock, C.O.; Zheng, J. The solution structure of acyl carrier protein from *Mycobacterium tuberculosis*. *J. Biol. Chem.* 2002, 277, 15874–15880. [CrossRef] [PubMed]

10. Rock, C.O.; Cronan, J.E. Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis. *Biochim. Biophys. Acta* 1996, 1302, 1–16. [CrossRef] [PubMed]

11. Brennan, P.J.; Nikaido, H. The envelope of mycobacteria. *Annu. Rev. Biochem.* 1995, 64, 29–63. [CrossRef] [PubMed]

12. Harris, N.L.; Presnell, S.R.; Cohen, F.E. Four helix bundle diversity in globular proteins. *J. Mol. Biol.* 1994, 236, 1356–1368. [CrossRef]

13. Buchko, G.W.; Hewitt, S.N.; Napuli, A.J.; Van Voorhis, W.C.; Myler, P.J. Solution-state NMR structure and biophysical characterization of zinc-substituted rubredoxin B (Rv3250c) from *Mycobacterium tuberculosis*. *Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.* 2011, 67, 1148–1153. [CrossRef] [PubMed]

14. Blake, P.R.; Park, J.B.; Zhou, Z.H.; Hare, D.R.; Adams, M.W.; Summers, M.F. Solution-state structure by NMR of zinc-substituted rubredoxin from the marine hyperthermophilic archaeabacterium Pyrococcus furiosus. *Biochim. Biophys. Acta* 1996, 1302, 1–16. [CrossRef] [PubMed]

15. Schweimer, K.; Hoffmann, S.; Wastl, J.; Maier, U.G.; Rosch, P.; Sticht, H. Solution structure of a zinc substituted eukaryotic rubredoxin from the cryptomonad alga Guillardia theta. *Protein Sci.* 2000, 9, 1474–1486. [CrossRef] [PubMed]

16. Dauter, Z.; Wilson, K.S.; Sieker, L.C.; Moulin, J.M.; Meyer, J. Zinc- and iron-rubredoxins from Clostridium pasteurianum at atomic resolution: A high-precision model of a ZnS4 coordination unit in a protein. *Proc. Natl. Acad. Sci. USA* 1996, 93, 8836–8840. [CrossRef] [PubMed]

17. Aravind, L.; Koonin, E.V. The STAS domain—A link between anion transporters and antisigma-factor antagonists. *Curr. Biol.* 2000, 10, R53–R55. [CrossRef]

18. Sharma, A.K.; Ye, L.; Baer, C.E.; Shannugusundaram, K.; Alber, T.; Alper, S.L.; Rigby, A.C. Solution structure of the guanine nucleotide-binding STAS domain of SLC26-related SulP protein Rv1739c from *Mycobacterium tuberculosis*. *J. Biol. Chem.* 2011, 286, 8534–8544. [CrossRef] [PubMed]

19. Cavet, J.S.; Meng, W.; Pennella, M.A.; Appelhoff, R.J.; Giedroc, D.P.; Robinson, N.J. A nickel-cobalt-sensing ArsR-SmtB family repressor. Contributions of cytosol and effector binding sites to metal selectivity. *J. Biol. Chem.* 2002, 277, 38441–38448. [CrossRef] [PubMed]
21. Busenlehner, L.S.; Pennella, M.A.; Giedroc, D.P. The SmtB/ArsR family of metalloregulatory transcriptional repressors: Structural insights into prokaryotic metal resistance. *FEMS Microbiol. Rev.* 2003, 27, 131–143. [CrossRef]

22. Osman, D.; Cavet, J.S. Bacterial metal-sensing proteins exemplified by ArsR-SmtB family repressors. *Nat. Prod. Rep.* 2010, 27, 668–680. [CrossRef] [PubMed]

23. Bortoluzzi, A.; Muskett, F.W.; Waters, L.C.; Addis, P.W.; Rieck, B.; Munder, T.; Schleier, S.; Forti, F.; Ghisotti, D.; Ma, C.; Yang, X.; Lewis, P.J. Bacterial transcription as a target for antibacterial drug development. *Proc. Natl. Acad. Sci. USA* 2010, 107, 5154–5159. [CrossRef] [PubMed]

24. Lee, C.W.; Chakravorty, D.K.; Chang, F.M.; Reyes-Caballero, H.; Ye, Y.; Merz, K.M., Jr.; Giedroc, D.P.; Macdonald, R.; Sarkar, D.; Amer, B.R.; Clubb, R.T. Solution structure of the PhoP DNA-binding domain from *Mycobacterium tuberculosis*. *Biochemistry* 2007, 46, 190–200. [CrossRef] [PubMed]

25. Roberts, J.W.; Shankar, S.; Filter, J.J. RNA polymerase elongation factors. *PLoS ONE* 2007, 2, e221. [CrossRef] [PubMed]

26. Strauss, M.; Schweimer, K.; Burmann, B.M.; Richter, A.; Guttler, S.; Wohrl, B.M.; Rosch, P.; Jungblut, P.R.; Cervenansky, C.; et al. Proteomic identification of RNA polymerase-binding protein A (RbpA) and its interactions with sigma factors. *J. Mol. Biol.* 2010, 394, 14438–14450. [CrossRef] [PubMed]

27. Ma, C.; Yang, X.; Lewis, P.J. Bacterial transcription as a target for antibacterial drug development. *Microbiol. Mol. Biol. Rev.* 2010, 68, 139–160. [CrossRef] [PubMed]

28. Bortoluzzi, A.; Muskett, F.W.; Waters, L.C.; Addis, P.W.; Rieck, B.; Munder, T.; Schleier, S.; Forti, F.; Ghisotti, D.; Carr, M.D.; et al. *Mycobacterium tuberculosis* NusG protein are dynamically independent. *J. Biomol. Struct. Dyn.* 2016, 34, 352–361. [CrossRef] [PubMed]

29. Manganelli, R.; Provvedi, R.; Rodrigue, S.; Beaucher, J.; Gaudreau, L.; Smith, I. Sigma factors and global gene regulation in *Mycobacterium tuberculosis*. *J. Bacteriol.* 2004, 186, 895–902. [CrossRef] [PubMed]

30. Hu, Y.; Morichaud, Z.; Chen, S.; Leonetti, J.P.; Brodolin, K. *Mycobacterium tuberculosis* RbpA protein is a new type of transcriptional activator that stabilizes the sigma A-containing RNA polymerase holoenzyme. *Nucleic. Acids. Res.* 2012, 40, 6547–6557. [CrossRef] [PubMed]

31. Walters, S.B.; Dubnau, E.; Kolesnikova, I.; Lavall, F.; Daffe, M.; Smith, I. The *Mycobacterium tuberculosis* PhoPR two-component system regulates genes essential for virulence and complex lipid biosynthesis. *Mol. Microbiol.* 2006, 60, 312–330. [CrossRef] [PubMed]

32. Gonzalo-Asensio, J.; Mostowy, S.; Harders-Westerveen, J.; Huygen, K.; Hernandez-Pando, R.; Thole, J.; Behr, M.; Gicquel, B.; Martin, C. PhoP: A missing piece in the intricate puzzle of *Mycobacterium tuberculosis* virulence. *PLoS ONE* 2008, 3, e3496. [CrossRef] [PubMed]

33. Pathak, A.; Goyal, R.; Sinha, A.; Sarkar, D. Domain structure of virulence-associated response regulator PhoP of *Mycobacterium tuberculosis*: Role of the linker region in regulator-promoter interaction(s). *J. Biol. Chem.* 2010, 285, 34309–34318. [CrossRef] [PubMed]

34. Macdonald, R.; Sarkar, D.; Amer, B.R.; Clubb, R.T. Solution structure of the PhoP DNA-binding domain from *Mycobacterium tuberculosis*. *J. Biol. Chem.* 2015, 63, 111–117. [CrossRef] [PubMed]

35. Gordon, B.R.; Imperial, R.; Wang, L.; Navarre, W.W.; Liu, J. Lsr2 of *Mycobacterium tuberculosis* represents a novel class of H-NS-like proteins. *J. Bacteriol.* 2008, 190, 7052–7059. [CrossRef] [PubMed]

36. Gordon, B.R.; Li, Y.; Wang, L.; Sintsova, A.; van Bakel, H.; Tian, S.; Navarre, W.W.; Xia, B.; Liu, J. Lsr2 is a nucleoid-associated protein that targets AT-rich sequences and virulence genes in *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. USA* 2010, 107, 5154–5159. [CrossRef] [PubMed]

37. Av-Gay, Y.; Everett, M. The eukaryotic-like Ser/Thr protein kinases of *Mycobacterium tuberculosis*. *Trends Microbiol.* 2000, 8, 238–244. [CrossRef]

38. Koul, A.; Choidas, A.; Treder, M.; Tyagi, A.K.; Drlica, K.; Singh, Y.; Ullrich, A. Cloning and characterization of secretory tyrosine phosphatases of *Mycobacterium tuberculosis*. *J. Bacteriol.* 2000, 182, 5425–5432. [CrossRef] [PubMed]

39. Villarino, A.; Duran, R.; Wehenkel, A.; Fernandez, P.; England, P.; Brodin, P.; Cole, S.T.; Zimmer-Arndt, U.; Jungblut, P.; Cervenansky, C.; et al. Proteomic identification of *M. tuberculosis* protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions. *J. Mol. Biol.* 2005, 350, 953–963. [CrossRef] [PubMed]
Cole, S.T.; Alzari, P.M. Towards new tuberculosis drugs. Biochem. Soc. Trans. 2007, 35, 1321–1324. [CrossRef] [PubMed]

Jones, G.; Dyson, P. Evolution of transmembrane protein kinases implicated in coordinating remodeling of gram-positive peptidoglycan: Inside versus outside. J. Bacteriol. 2006, 188, 7470–7476. [CrossRef] [PubMed]

Barthe, P.; Mukamolova, G.V.; Roumestand, C.; Cohen-Gonsaud, M. The structure of PknB extracellular PASTA domain from Mycobacterium tuberculosis suggests a ligand-dependent kinase activation. Structure 2010, 18, 606–615. [CrossRef] [PubMed]

Kang, C.M.; Abbott, D.W.; Park, S.T.; Dascher, C.C.; Cantley, L.C.; Husson, R.N. The Mycobacterium tuberculosis serine/threonine kinases PknA and PknB: Substrate identification and regulation of cell shape. Genes Dev. 2005, 19, 1692–1704. [CrossRef] [PubMed]

Nott, T.J.; Kelly, G.; Stach, L.; Li, J.; Westcott, S.; Patel, D.; Hunt, D.M.; Howell, S.; Buxton, R.S.; O’Hare, H.M.; et al. An intramolecular switch regulates phosphoindependent FHA domain interactions in Mycobacterium tuberculosis. Sci. Signal. 2009, 2, ra12. [CrossRef] [PubMed]

Roumestand, C.; Leiba, J.; Galophe, N.; Margeat, E.; Padilla, A.; Bessin, Y.; Barthe, P.; Molle, V.; Cohen-Gonsaud, M. Structural insight into the Mycobacterium tuberculosis Rv0020c protein and its interaction with the PknB kinase. Structure 2011, 19, 1525–1534. [CrossRef] [PubMed]

Cohen-Gonsaud, M.; Barthe, P.; Canova, M.J.; Stagier-Simon, C.; Kremer, L.; Roumestand, C.; Molle, V. The Mycobacterium tuberculosis Ser/Thr kinase substrate Rv2175c is a DNA-binding protein regulated by phosphorylation. J. Biol. Chem. 2009, 284, 19290–19300. [CrossRef] [PubMed]

Bach, H.; Papavinasasundaram, K.G.; Wong, D.; Hmama, Z.; Aw-Gay, Y. Mycobacterium tuberculosis virulence is mediated by PtpA dephosphorylation of human vacuolar protein sorting 33B. Cell Host Microbe 2008, 3, 316–322. [CrossRef] [PubMed]

Steble, T.; Seeramulu, S.; Lohr, F.; Richter, C.; Saxena, K.; Jonker, H.R.; Schwalbe, H. The apo-structure of the low molecular weight protein-tyrosine phosphatase A (MptP A) from Mycobacterium tuberculosis allows for better target-specific drug development. J. Biol. Chem. 2012, 287, 34569–34582. [CrossRef] [PubMed]

Van Rompay, A.R.; Johansson, M.; Karlsson, A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol. Ther. 2000, 87, 189–198. [CrossRef]

Munier-Lehmann, H.; Burlacu-Miron, S.; Craescu, C.T.; Mantsch, H.H.; Schultz, C.P. A new subfamily of short bacterial adenylate kinases with the Mycobacterium tuberculosis enzyme as a model: A predictive and experimental study. Proteins 1999, 36, 238–248. [CrossRef]

Miron, S.; Munier-Lehmann, H.; Craescu, C.T. Structural and dynamic studies on ligand-free adenylate kinase from Mycobacterium tuberculosis revealed a closed conformation that can be related to the reduced catalytic activity. Biochemistry 2004, 43, 67–77. [CrossRef] [PubMed]

Mukamolova, G.V.; Kaprelyants, A.S.; Young, D.I.; Young, M.; Kell, D.B. A bacterial cytokine. Proc. Natl. Acad. Sci. USA 1998, 95, 8916–8921. [CrossRef] [PubMed]

Downing, K.J.; Mischenko, V.V.; Shleeva, M.O.; Young, D.I.; Young, M.; Kaprelyants, A.S.; Apt, A.S.; Mizrahi, V. Mutants of Mycobacterium tuberculosis lacking three of the five rpf-like genes are defective for growth in vivo and for resuscitation in vitro. Infect. Immun. 2005, 73, 3038–3043. [CrossRef] [PubMed]

Mukamolova, G.V.; Turapov, O.A.; Young, D.I.; Kaprelyants, A.S.; Kell, D.B.; Young, M. A family of autocrine growth factors in Mycobacterium tuberculosis. Mol. Microbiol. 2002, 46, 623–635. [CrossRef] [PubMed]

Cohen-Gonsaud, M.; Barthe, P.; Bagneris, C.; Henderson, B.; Ward, J.; Roumestand, C.; Keep, N.H. The structure of a resuscitation-promoting factor domain from Mycobacterium tuberculosis shows homology to lysozymes. Nat. Struct. Mol. Biol. 2005, 12, 270–273. [CrossRef] [PubMed]

Maione, V.; Ruggiero, A.; Russo, L.; De Simone, A.; Pedone, P.V.; Malgieri, G.; Berisio, R.; Isernia, C. NMR Structure and Dynamics of the Resuscitation Promoting Factor RpfC Catalytic Domain. PLoS ONE 2015, 10, e0142807. [CrossRef] [PubMed]

Walsh, M.A.; Schneider, T.R.; Sieker, L.C.; Dauter, Z.; Lamzin, V.S.; Wilson, K.S. Refinement of triclinic hen egg-white lysozyme at atomic resolution. Acta Crystallogr. Sect. D 1998, 54, 522–546. [CrossRef]
59. Bal, N.C.; Agrawal, H.; Meher, A.K.; Arora, A. Characterization of peptidyl-tRNA hydrolase encoded by open reading frame Rv1014c of Mycobacterium tuberculosis H37Rv. Biol. Chem. 2007, 88, 467–479. [CrossRef] [PubMed]

60. Pulavarthi, S.V.; Jain, A.; Pathak, P.P.; Mahmood, A.; Arora, A. Solution structure and dynamics of peptidyl-tRNA hydrolase from Mycobacterium tuberculosis H37Rv. J. Mol. Biol. 2008, 378, 165–177. [CrossRef] [PubMed]

61. Alix, E.; Blanc-Potard, A.B. MgtC: A key player in intramacrophage survival. Trends Microbiol. 2007, 15, 252–256. [CrossRef] [PubMed]

62. Yang, Y.; Labesse, G.; Carrere-Kremer, S.; Esteves, K.; Kremer, L.; Cohen-Gonsaud, M.; Blanc-Potard, A.B. The C-terminal domain of the virulence factor MgtC is a divergent ACT domain. J. Bacteriol. 2012, 194, 6255–6263. [CrossRef] [PubMed]

63. Arner, E.S.; Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 2000, 267, 6102–6109. [CrossRef] [PubMed]

64. Akif, M.; Khare, G.; Tyagi, A.K.; Mande, S.C.; Sardesai, A.A. Functional studies of multiple thioredoxins from Mycobacterium tuberculosis. J. Bacteriol. 2008, 190, 7087–7095. [CrossRef] [PubMed]

65. Olson, A.L.; Neumann, T.S.; Cai, S.; Sem, D.S. Solution structures of Mycobacterium tuberculosis thioredoxin C and models of intact thioredoxin system suggest new approaches to inhibitor and drug design. Proteins 2013, 81, 675–689. [CrossRef] [PubMed]

66. Rawat, M.; Newton, G.L.; Ko, M.; Martinez, G.J.; Fahey, R.C.; Av-Gay, Y. Mycothiol-deficient Mycobacterium smegmatis mutants are hypersensitive to alkylating agents, free radicals, and antibiotics. Antimicrob. Agents Chemother. 2002, 46, 3348–3355. [CrossRef] [PubMed]

67. Van Laer, K.; Buts, L.; Foppen, N.; Vertommen, D.; Van Belle, K.; Wahrn, K.; Roos, G.; Nilsson, L.; Mateos, L.M.; Rawat, M.; et al. Mycoredoxin-1 is one of the missing links in the oxidative stress defence mechanism of Mycobacteria. Mol. Microbiol. 2012, 86, 787–804. [CrossRef] [PubMed]

68. Martin, J.L. Thioredoxin—A fold for all reasons. Structure 1995, 3, 245–250. [CrossRef]

69. Ratledge, C. Iron, mycobacteria and tuberculosis. Tuberculosis 2004, 84, 110–130. [CrossRef] [PubMed]

70. Somu, R.V.; Boshoff, H.; Qiao, C.; Bennett, E.M.; Barry, C.E., 3rd; Aldrich, C.C. Rationally designed nucleoside tuberculosis pathogenesis to inherited human corneal disease. J. Biol. Chem. 2003, 278, 43736–43743. [CrossRef] [PubMed]
79. Clout, N.J.; Tisi, D.; Hohenester, E. Novel fold revealed by the structure of a FAS1 domain pair from the insect cell adhesion molecule fasciclin I. *Structure* **2003**, *11*, 197–203. [CrossRef]

80. Wang, Z.; Potter, B.M.; Gray, A.M.; Sacksteder, K.A.; Geisbrecht, B.V.; Laity, J.H. The solution structure of antigen MPT64 from *Mycobacterium tuberculosis* defines a new family of beta-grasp proteins. *J. Mol. Biol.* **2007**, *366*, 375–381. [CrossRef] [PubMed]

81. Kumar, V.G.; Urs, T.A.; Ranganath, R.R. MPT 64 Antigen detection for Rapid confirmation of *M. tuberculosis* isolates. *BMC Res. Notes* **2011**, *4*, 79. [CrossRef] [PubMed]

82. Arora, J.; Kumar, G.; Verma, A.K.; Bhalla, M.; Sarin, R.; Myneedu, V.P. Utility of MPT64 Antigen Detection for Rapid Confirmation of *Mycobacterium tuberculosis* Complex. *J. Glob. Infect. Dis.* **2015**, *7*, 66–69. [PubMed]

83. Abdallah, A.M.; Gey van Pittius, N.C.; Champion, P.A.; Cox, J.; Luirink, J.; Vandenbroucke-Grauls, C.M.; Appelmelk, B.J.; Bitter, W. Type VII secretion—Mycobacteria show the way. *Nat. Rev. Microbiol.* **2007**, *5*, 883–891. [CrossRef] [PubMed]

84. Davis, J.M.; Ramakrishnan, L. The role of the granuloma in expansion and dissemination of early tuberculous infection. *Cell* **2009**, *136*, 37–49. [CrossRef] [PubMed]

85. Abdallah, A.M.; Savage, N.D.; van Zon, M.; Wilson, L.; Vandenbroucke-Grauls, C.M.; van der Wel, N.N.; Ottenhoff, T.H.; Bitter, W. The ESX-5 secretion system of Mycobacterium marinus modulates the macrophage response. *J. Immunol.* **2008**, *181*, 7166–7175. [CrossRef] [PubMed]

86. Siegrist, M.S.; Unnikrishnan, M.; McConnell, M.J.; Borowsky, M.; Cheng, T.Y.; Siddiqi, N.; Fortune, S.M.; Moody, D.B.; Rubin, E.J. Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 18792–18797. [CrossRef] [PubMed]

87. Draper, P. The functions of OmpATb, a pore-forming protein of *Mycobacterium tuberculosis*. *Cell* **2003**, *113*, 826–837. [CrossRef] [PubMed]

88. Abdallah, A.M.; Gey van Pittius, N.C.; Champion, P.A.; Cox, J.; Luirink, J.; Vandenbroucke-Grauls, C.M.; Appelmelk, B.J.; Bitter, W. Type VII secretion—Mycobacteria show the way. *Nat. Rev. Microbiol.* **2007**, *5*, 883–891. [CrossRef] [PubMed]

89. Ilghari, D.; Lightbody, K.L.; Veverka, V.; Waters, L.C.; Musket, F.W.; Renshaw, P.S.; Carr, M.D. Solution activity of OmpATb from *Mycobacterium tuberculosis* and characterization of the channel by peptidic dissection. *J. Biol. Chem.* **2011**, *286*, 29993–30002. [CrossRef] [PubMed]

90. Wang, Z.; Potter, B.M.; Gray, A.M.; Sacksteder, K.A.; Geisbrecht, B.V.; Laity, J.H. The solution structure of antigen MPT64 from *Mycobacterium tuberculosis* defines a new family of beta-grasp proteins. *J. Mol. Biol.* **2007**, *366*, 375–381. [CrossRef] [PubMed]

91. Bitter, W.; Houben, E.N.; Bottai, D.; Brodin, P.; Brown, E.J.; Cox, J.S.; Derbyshire, K.; Fortune, S.M.; Gao, L.Y.; Liu, J.; et al. Systematic genetic nomenclature for type VII secretion systems. *PLoS Pathog.* **2009**, *5*, e1000507. [CrossRef] [PubMed]

92. Bittner, P.S.; Panagiotidou, P.; Whelan, A.; Hewinson, R.G.; Renshaw, P.S.; Hewinson, R.G.; Burke, B.; Norman, J.; et al. Structure and function of the complex formed by the tuberculosis OmpATb operon accelerates ammonia secretion and adaptation of *Mycobacterium tuberculosis* to acidic environments. *Mol. Microbiol.* **2011**, *80*, 900–918. [CrossRef] [PubMed]
96. Teriete, P.; Yao, Y.; Kolodzik, A.; Yu, J.; Song, H.; Niederweis, M.; Marassi, F.M. *Mycobacterium tuberculosis* Rv0899 adopts a mixed alpha/beta-structure and does not form a transmembrane beta-barrel. *Biochemistry* **2010**, *49*, 2768–2777. [CrossRef] [PubMed]

97. Yang, Y.; Auguin, D.; Delbecq, S.; Dumas, E.; Molle, G.; Molle, V.; Roumestand, C.; Saint, N. Structure of the *Mycobacterium tuberculosis* OmpATb protein: A model of an oligomeric channel in the mycobacterial cell wall. *Proteins* **2011**, *79*, 645–661. [CrossRef] [PubMed]

98. Li, J.; Shi, C.; Gao, Y.; Wu, K.; Shi, P.; Lai, C.; Chen, L.; Wu, F.; Tian, C. Structural studies of *Mycobacterium tuberculosis* Rv0899 reveal a monomeric membrane-anchoring protein with two separate domains. *J. Mol. Biol.* **2012**, *415*, 382–392. [CrossRef] [PubMed]

99. Yao, Y.; Barghava, N.; Kim, J.; Niederweis, M.; Marassi, F.M. Molecular structure and peptidoglycan recognition of *Mycobacterium tuberculosis* ArfA (Rv0899). *J. Mol. Biol.* **2012**, *416*, 208–220. [CrossRef] [PubMed]

100. Yeats, C.; Bateman, A. The BON domain: A putative membrane-binding domain. *Trends Biochem. Sci.* **2003**, *28*, 352–355. [CrossRef] [PubMed]

101. Pautsch, A.; Schulz, G.E. High-resolution structure of the OmpA membrane domain. *J. Mol. Biol.* **2000**, *298*, 273–282. [CrossRef] [PubMed]

102. Buchko, G.W.; Phan, I.; Myler, P.J.; Terwilliger, T.C.; Kim, C.Y. Inaugural structure from the DUF3349 superfamily of proteins, *Mycobacterium tuberculosis* Rv0543c. *Arch. Biochem. Biophys.* **2011**, *506*, 150–156. [CrossRef] [PubMed]

103. Rath, P.; Huang, C.; Wang, T.; Wang, T.; Li, H.; Prados-Rosales, R.; Elemento, O.; Casadevall, A.; Nathan, C.F. Genetic regulation of vesiculogenesis and immunomodulation in *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, E4790–E4797. [CrossRef] [PubMed]

104. Calvanese, L.; Falcigno, L.; Maglione, C.; Marasco, D.; Ruggiero, A.; Squeglia, F.; Berisio, R.; D’Auria, G. Structural and binding properties of the PASTA domain of PonA2, a key penicillin-binding protein from *Mycobacterium tuberculosis*. *Biopolymers* **2014**, *101*, 712–719. [CrossRef] [PubMed]

105. Sauvage, E.; Kerff, F.; Terrak, M.; Ayala, J.A.; Charlier, P. The penicillin-binding proteins: Structure and role in peptidoglycan biosynthesis. *FEMS Microb. Rev.* **2008**, *32*, 234–258. [CrossRef] [PubMed]

106. Barthe, P.; Veyron-Churlet, R.; de Visch, A.; Gilleron, M.; Saliou, J.M.; Tomavo, S.; Nigou, J.; Brodin, P.; Cohen-Gonsaud, M. *Mycobacterium tuberculosis* LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization. *Structure* **2016**, *24*, 1788–1794. [CrossRef] [PubMed]

107. Brodin, P.; Poquet, Y.; Levillain, F.; Peguillet, I.; Larrouy-Maumus, G.; Gilleron, M.; Ewann, F.; Christophe, T.; Fenistein, D.; Jang, J.; et al. High content phenotypic cell-based visual screen identifies *Mycobacterium tuberculosis* acyltrehalose-containing glycolipids involved in phagosome remodeling. *PLoS Pathog.* **2010**, *6*, e1001100. [CrossRef] [PubMed]

108. Meyer, B.; Peters, T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. *Angew. Chem. Int. Ed. Engl.* **2003**, *42*, 864–890. [CrossRef] [PubMed]

109. Williamson, M.P. Using chemical shift perturbation to characterise ligand binding. *Prog. Nucl. Magn. Reson. Spectrosc.* **2013**, *73*, 1–16. [CrossRef] [PubMed]

110. Dominguez, C.; Boelens, R.; Bonvin, A.M. HADDOCK: A protein-protein docking approach based on biochemical or biophysical information. *J. Am. Chem. Soc.* **2003**, *125*, 1731–1737. [CrossRef] [PubMed]

111. Bach, H.; Wong, D.; Av-Gay, Y. *Mycobacterium tuberculosis* PtkA is a novel protein tyrosine kinase whose substrate is PtpA. *Biochem. J.* **2009**, *420*, 155–160. [CrossRef] [PubMed]

112. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. *Angew. Chem. Int. Ed.* **1999**, *38*, 1784–1788. [CrossRef]

113. Dalvit, C.; Pevarello, P.; Tato, M.; Veronesi, M.; Vulpetti, A.; Sundstrom, M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. *J. Biomol. NMR* **2000**, *18*, 65–68. [CrossRef] [PubMed]

114. Morris, K.F.; Johnson, C.S., Jr. Diffusion-ordered two-dimensional nuclear magnetic resonance spectroscopy. *J. Am. Chem. Soc.* **1992**, *114*, 3139–3141. [CrossRef]
116. Nassau, P.M.; Martin, S.L.; Brown, R.E.; Weston, A.; Monsey, D.; McNeil, M.R.; Duncan, K. Galactofuranose biosynthesis in Escherichia coli K-12: Identification and cloning of UDP-galactopyranose mutase. *J. Bacteriol.* 1996, 178, 1047–1052. [CrossRef] [PubMed]

117. Pan, F.; Jackson, M.; Ma, Y.; McNeil, M. Cell wall core galactofuran synthesis is essential for growth of mycobacteria. *J. Bacteriol.* 2001, 183, 3991–3998. [CrossRef] [PubMed]

118. Brennan, P.J. Structure, function, and biogenesis of the cell wall of *Mycobacterium tuberculosis*. *Tuberculosis* 2003, 83, 91–97. [CrossRef]

119. Shi, Y.; Colombo, C.; Kuttiyatveetil, J.R.; Zalatar, N.; van Straaten, K.E.; Mohan, S.; Sanders, D.A.; Pinto, B.M. A Second, Druggable Binding Site in UDP-Galactopyranose Mutase from *Mycobacterium tuberculosis*? *ChemBiochem* 2016, 17, 2264–2273. [CrossRef] [PubMed]

120. Ouellet, H.; Johnston, J.B.; Ortiz de Montellano, P.R. The *Mycobacterium tuberculosis* cytochrome P450 system. *Arch. Biochem. Biophys.* 2010, 493, 82–95. [CrossRef] [PubMed]

121. McLean, K.J.; Belcher, J.; Driscoll, M.D.; Fernandez, C.C.; Le Van, D.; Bui, S.; Golovanova, M.; Munro, A.W. The *Mycobacterium tuberculosis* cytochromes P450: Physiology, biochemistry & molecular intervention. *Future Med. Chem.* 2010, 2, 1339–1353. [PubMed]

122. Hudson, S.A.; McLean, K.J.; Munro, A.W.; Abell, C. *Mycobacterium tuberculosis* cytochrome P450 enzymes: A cohort of novel TB drug targets. *Biochem. Soc. Trans.* 2012, 40, 573–579. [CrossRef] [PubMed]

123. Belin, P.; Le Du, M.H.; Fielding, A.; Lequin, O.; Jacquet, M.; Charbonnier, J.B.; Lecoq, A.; Thai, R.; Courcon, M.; Masson, C.; et al. Identification and structural basis of the reaction catalyzed by CYP121, an essential cytochrome P450 in *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. USA* 2009, 106, 7426–7431. [CrossRef] [PubMed]

124. McLean, K.J.; Carroll, P.; Lewis, D.G.; Dunford, A.J.; Seward, H.E.; Neeli, R.; Cheesman, M.R.; Marsollier, L.; Douglas, P.; Smith, W.E.; et al. Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of *Mycobacterium tuberculosis* H37Rv. *J. Biol. Chem.* 2008, 283, 33406–33416. [CrossRef] [PubMed]

125. Odds, F.C.; Brown, A.J.; Gow, N.A. Antifungal agents: Mechanisms of action. *Trends Microbiol.* 2003, 11, 272–279. [CrossRef]

126. Hudson, S.A.; McLean, K.J.; Surade, S.; Yang, Y.Q.; Leys, D.; Ciulli, A.; Munro, A.W.; Abell, C. Application of fragment screening and merging to the discovery of inhibitors of the *Mycobacterium tuberculosis* cytochrome P450 CYP121. *Angew. Chem. Int. Ed. Engl.* 2012, 51, 9311–9316. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).